Back to Research Home
PAHCPhibro Animal Health Corporation
Health Care · Biotechnology: Pharmaceutical Preparations · Small
$38.80−2.54%
As of 23 Oct 2026Mkt cap $1.6B
Stage 13
WATCH
Fundamentals
41.9/75
Technical
6.6/15
Independent
48.5/90
GCAE viewbusiness is credible but technical recovery is not yet actionable
Price
- 1M
- +14.4%
- 3M
- +10.1%
- 6M
- −29.7%
- 1Y
- −3.5%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 15.9xHist median 26.2x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 161.1x
- FCF yield
- 0.6%
Quality
- ROIC
- 14.7%
- Operating margin
- 8.5%
- FCF margin
- 0.6%
- Current ratio
- 3.0x
Growth
- Revenue growth
- +17.1%Latest FY YoY
- Revenue CAGR
- +12.7%
- EPS CAGR
- +19.0%
- FCF CAGR
- −53.9%
Capital
- Share-count trend
- +0.5%3Y annualised
- Net debt
- $676M9.8x OCF
Annual trend
- CAGR 2022–2026
- +12.7%
- Latest · 2026
- $2B
- YoY
- +17.1%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
business is credible but technical recovery is not yet actionable
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-04
More details & evidence
Production decision
- Stage 13
- WATCH
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded